Erlotinib Completed Phase 2 Trials for Myelodysplastic Syndrome Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00977548Erlotinib Study for Myelodysplastic Syndrome (MDS)